Sm-p80-based schistosomiasis vaccine: Preparation for human clinical trials

摘要

Mass anti-parasitic drug administration programs and other control strategies have made important contributions in reducing the global prevalence of helminths. Schistosomiasis, however, continues to spread to new geographic areas. Advent of a viable vaccine and its deployment coupled with existing control efforts is expected to make a significant headway towards a sustained schistosomiasis control. In 2016, Science ranked schistosomiasis vaccine as one of the top 10 vaccines that need to be urgently developed. A vaccine that is effective against geographically distinct forms of intestinal/hepatic and urinary disease is essential to make a meaningful impact in global reduction of disease burden. In this review we focus on salient features of schistosomiasis vaccines in different phases of the clinical development pipeline and highlight the Sm-p80-based vaccine which is now being prepared for human clinical trials.